Jul 9, 2026
AstraZeneca and Ionis' heart disease drug Wainua fails pivotal trial, shares plunge
AstraZeneca's shares fell as much as 9% after Wainua, a drug developed with Ionis Pharmaceuticals, unexpectedly failed to meet its primary endpoint in a late-stage trial for ATTR-CM heart disease. The failure has raised concerns about the company's trial design and shaken investor confidence.
4 sources
00